Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 101-120 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 101 | Orbitworks lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources' membership rationale says Orbitworks is an Abu Dhabi satellite integrator planning a 50-satellite AI-powered Earth observation constellation and participating in a SAR satellite program. If accurate and current, that implies meaningful long-horizon platform and constellation buildout opportunity, but the reviewed sources lack direct supporting summaries or available evidence. Why now: The rationale references growth-oriented planned activity, which is relevant to a 1 year+ horizon, yet timing confidence is limited because coverage data shows no evidence after recent evidence window. Caveats: Membership rationale references article IDs, and: but and article summaries are not provided in the reviewed sources. No direct positive_evidence or negative_evidence arrays are populated. Opportunity is based on stated plans, not validated conversion, contracts, or operating milestones inside the recent evidence window. |
| 102 | Overview Energy lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence rationale says Overview Energy won a U.S. Air Force contract for orbit-to-grid energy technology using geosynchronous satellites and space-based solar power. A defense contract in an ambitious emerging category is positive for strategic validation over a 1 year+ horizon. Why now: The likely catalyst is the reported Air Force contract, yet the reviewed sources gives no retained article summary or evidence row to establish recency or contract scale. Caveats: Phase2 membership rationale references: but no article summary or evidence are available. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 103 | Pacific Defense lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence context says Pacific Defense launched the Moonraker payload, described as the first on-orbit demo of a reprogrammable payload for SSA/EMSO, developed under an AFRL contract. An on-orbit demo tied to a government contract is stronger business progress context than most peers in this screen and could support longer-horizon defense-space opportunity if follow-on adoption occurs. Why now: The company appears more advanced than several peers because the reviewed sources references an on-orbit demo under contract, but there is no citable recency signal beyond membership support article ID: and no available evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary for citation. Opportunity score is relative within a weak-evidence batch, not high absolute conviction. |
| 104 | Portal Space Systems lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence rationale says Portal Space Systems raised a $50M Series A and offers commercial debris removal as a service with its Starburst spacecraft, which is directionally positive for a long-horizon growth thesis if validated. Why now: Potential why-now would be the reported Series A and service positioning, but recency cannot be verified because no evidence are retained after the recent evidence window. Caveats: Phase2 membership rationale references: but no article summary or evidence are included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Slightly higher opportunity than some peers only because the reviewed sources rationale mentions both financing and product/service positioning. |
| 105 | QOSMIC lowweak | Opp 4 Risk 2 | Thesis: QOSMIC has some opportunity potential because reviewed sources context says it raised about $3.3 million in seed funding to build optical communications infrastructure for space, with proceeds intended for engineering expansion, manufacturing scale-up, and deployment of optical communication terminals. That indicates an early-stage capital infusion tied to product buildout, but the evidence is undated and article-level rather than direct dated event evidence. Why now: Why now is weak because the only support is undated context articles; the reviewed sources explicitly says no is available, so recency-sensitive claims should be treated cautiously for these funding and expansion statements Evidence
Caveats: Evidence is undated; recency is uncertain. Support is supporting article context only, not direct structured positive event evidence. Same funding story appears in two articles and should not be treated as independent confirmation. |
| 106 | Quantum Space lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources membership rationale says Quantum Space was selected by the U.S. Space Force for the Andromeda space monitoring satellite program. If current and material, that indicates credible government-program positioning in a strategically durable market. Why now: The reviewed sources provide no post-recent evidence window detailed evidence, but the membership rationale specifically references selection for the Andromeda program via article. Because the underlying article summary/ is not included here, timing and magnitude are uncertain. Caveats: No representative article or is included for the cited Andromeda selection evidence. Selection for a program is positive, but without award size or timing the business impact is unclear. Scores are capped by missing direct article-level support. |
| 107 | Sierra Nevada Corporation mediummedium | Opp 4 Risk 2 | Thesis: Sierra Nevada Corporation has the strongest available reviewed sources signal because a within the recent evidence window article says Space Systems Command awarded more than $1.8 billion in Andromeda contracts and included Sierra Space among the awarded companies, indicating participation in a potentially durable U.S. national-security space program if the Sierra Space/Sierra Nevada linkage holds. Why now: The key surviving context is dated April 8, 2026, within the 90-day recent evidence window, and references recent contract awards under Andromeda that could matter over a 1 year+ horizon if they convert into meaningful program work. Article timestamp: April 8, 2026, basis: source date. Evidence is from at Evidence
Caveats: Evidence is supporting article context, not a direct structured positive event row for Sierra Nevada Corporation. Reviewed evidence explicitly notes entity-resolution ambiguity between Sierra Nevada Corporation and Sierra Space. The second representative article is older than the 90-day recent evidence window and should not drive recency, published September 2, 2025. |
| 108 | SpinLaunch lowweak | Opp 4 Risk 4 | Thesis: Reviewed evidence context says SpinLaunch's Meridian Space broadband constellation has 280 satellites being built. If accurate and current, that implies a tangible manufacturing/program buildout that could become strategically meaningful over a 1 year+ horizon. Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation. |
| 109 | Starcloud lowweak | Opp 4 Risk 2 | Thesis: Starcloud has the strongest relative opportunity case in this screen, albeit still low-conviction, because the reviewed sources' membership rationale references a reported $170M Series A and orbital AI/data-center activity. For a 1 year+ horizon, fundraising plus infrastructure ambition could matter if execution follows, but the reviewed sources provide no direct positive evidence, no, and no validated chronology inside the recent evidence window. Why now: If the fundraising and product positioning are recent, they could support a multi-quarter buildout story, but the reviewed sources explicitly shows zero available evidence after recent evidence window, so recency and sequencing cannot be confirmed. Caveats: Most supportive facts appear only in membership rationale, not available evidence. Reported funding cannot be treated as fully validated without direct article support in reviewed sources. No, quote, or dated direct summary is available. |
| 110 | Stelleo lowweak | Opp 4 Risk 2 | Thesis: Stelleo has some opportunity appeal because recent company-context evidence positions it as a Polish Earth Observation startup turning satellite intelligence into operational decisions for infrastructure, agriculture, and environmental users across Europe, suggesting a commercially relevant application layer. Why now: The article is within the recent evidence window and dated May 25, 2026, but it is a company-site style description rather than an independently reported business event, so it supports relevance more than momentum Evidence
Caveats: Evidence is article-level company context, not a direct commercial milestone. No direct traction, financing, or contract evidence is provided. Same-article repeated rows are not independent confirmation. |
| 111 | ThinkOrbital lowweak | Opp 4 Risk 3 | Thesis: ThinkOrbital has a speculative long-horizon opportunity signal because a dated May 2026 company-context article describes products spanning space domain awareness and in-space servicing, including ThinkX and a robotic arm/end effector. That suggests exposure to strategically important capability areas if the products convert into funded programs. Why now: Why now is the dated company-context article from May 28, 2026, recent within the recent evidence window, but it is still weak grounding because it is article-level website context rather than a confirmed business event. Evidence
Caveats: Evidence is article-level website context, not direct contract or financing evidence. Single-source evidence limits corroboration. No dated proof of revenue, customer adoption, or deployment is included. |
| 112 | Viasat, Inc. mediummedium | Opp 4 Risk 2 | Thesis: Viasat has modest opportunity support from recent supporting article context showing it was selected as a prime contractor in the U.S. Space Force Protected Tactical Satcom-Global program and that Rocket Lab will supply the spacecraft bus for Viasat's PTS-G satellite, indicating active participation in a next-generation military satcom program. Why now: Recent context exists within the recent evidence window: is dated June 11, 2026 and states Viasat was among operators selected under a combined $437.7 million award and has a defined supplier stack for its PTS-G satellite, which could matter over a 1 year+ horizon. Source date basis is source date. Evidence
Caveats: This is supporting article context only; the reviewed sources classifies it under weak context, so it is weaker than direct event/fact evidence. Same article appears in two weak-context rows and should not be treated as independent confirmation. An older Viasat company-hosted article exists but is outside recent evidence window, February 29, 2024 |
| 113 | Volta Space Technologies lowweak | Opp 4 Risk 5 | Thesis: Volta Space Technologies has an interesting long-horizon speculative opportunity because the reviewed sources rationale says it is developing a lunar laser power transmission system, with a 2028 demonstration planned and a payload booked on Firefly's Blue Ghost Mission 2. Why now: The rationale cites article and says the company has a 2028 demonstration planned with payload booked on Blue Ghost Mission 2, which is relevant to a 1 year+ strategic horizon but weak for immediate evidence-based ranking because no article body or is visible. Caveats: No visible representative article, quote, or in the reviewed sources body. The main cited demonstration is scheduled for 2028, so commercial payoff may sit beyond the stated 1 year+ ranking horizon. The Firefly payload linkage cannot be used as counterparty propagation evidence beyond the explicit rationale. |
| 114 | VyomIC lowweak | Opp 4 Risk 3 | Thesis: The membership rationale describes VyomIC as a Bengaluru-based New Space startup deploying a private global PNT satellite constellation in LEO, with first satellites planned for 2027 and 2028. That suggests large strategic upside over a 1 year+ horizon if financing and execution continue. Why now: Why now is moderate only because the business is framed around future constellation deployment and milestone timing beyond the immediate term; however, recency cannot be validated because no recent evidence window evidence are available. Caveats: Membership rationale cites article IDs and, but no are present. No representative article text or direct event/facts are available after the 90-day recent evidence window. Scoring reflects early-stage optionality and execution risk, not direct verified traction. |
| 115 | Wyvern lowweak | Opp 4 Risk 4 | Thesis: Wyvern has a plausible long-term opportunity in hyperspectral Earth observation. The reviewed sources say the company launched commercial hyperspectral satellites in 2023 and claims to be the only commercial provider with a ready-to-task constellation, which, if current, suggests existing capacity and differentiated imagery access. Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing. Evidence
Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown. |
| 116 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: Membership rationale says AAC Clyde Space signed a EUR 10.9 million ESA contract for a 12-satellite VDES constellation, which would be meaningful positive evidence for a 1 year+ horizon if directly available, but these reviewed sources provide no surviving evidence or article summaries to substantiate the current state beyond the rationale reference (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 117 | Agnikul lowweak | Opp 3 Risk 2 | Thesis: Agnikul appears to have credible long-horizon opportunity potential because the reviewed sources places it among Indian spacetech beneficiaries and identifies it as 'launch infrastructure' in one summary, suggesting sector exposure that could matter over a year-plus horizon if operating milestones follow. Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence. Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window. |
| 118 | Arctus Aerospace lowweak | Opp 3 Risk 2 | Thesis: Arctus Aerospace has a modestly better long-horizon opportunity case than most peers in this screen because the reviewed sources rationale states it raised $2.6M and is developing HALE UAVs for earth observation, indicating financing plus product development progress (: no provided in reviewed sources). Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts. |
| 119 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: Reviewed evidence membership rationale says Astrolab received NASA moon-base/lunar-terrain-vehicle related contract support, which could be favorable over a 1 year+ horizon if active, but no available article evidence remains to support a stronger current ranking. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 120 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: Membership rationale states Axelspace is launching seven GRUS-3 Earth observation microsatellites and expanding its constellation to more than 10 satellites, which would support an opportunity thesis tied to capacity expansion, but no direct evidence or article summaries are available in the reviewed sources after recent evidence window (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
Risk view
Showing rows 21-40 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 21 | Capella Space highstrong | Opp 8 Risk 4 | Thesis: Risk is present but not thesis-dominant: Capella is undertaking defense-oriented prototype work and broader strategic expansion beyond commercial SAR, which can carry execution complexity, but the reviewed sources contain no direct adverse evidence within the recent evidence window. Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure. Evidence
Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and |
| 22 | Cowboy Space mediummedium | Opp 7 Risk 4 | Thesis: Execution risk is meaningful because the business combines new rocket development with orbital data-center infrastructure, and one cited article says the first launch is expected before the end of 2028, implying a long path from capital raise to operational proof. Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028 Evidence
Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency. |
| 23 | Eutelsat Communications SA mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the ranking payload contains no kept direct evidence or representative articles for those claims, so the thesis depends on membership-support statements without available article detail, economics, or recency granularity beyond inclusion in the recent evidence windowed reviewed sources. Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration. Evidence
Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload. |
| 24 | GalaxEye mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources does not provide direct evidence of post-launch operational performance, customer revenue conversion, or successful scaling beyond the first satellite. Funding references are inconsistent across articles, and planned next-round financing after commissioning indicates continued capital dependence. Why now: The key timing change is that earlier pre-launch coverage from April 23, 2026 was followed by launch coverage on May 3, 2026/May 4, 2026, and later June 16, 2026 context states the first satellite was launched in May 2026, confirming a business-state transition from concept/pre-launch to deployed asset status. The NSIL resale agreement was reported earlier on February 13, 2026, giving a potential go-to-market bridge once satellite data is available. Evidence
Caveats: Most reviewed sources rows are neutral facts or supporting article context rather than explicit positive evidence. Funding totals vary across articles (~$14.5M, $18.3M, ~$20M), so exact capitalization is uncertain |
| 25 | Globalstar lowweak | Opp 3 Risk 4 | Thesis: Risk is moderate because evidence coverage is absent inside the 90-day recent evidence window, making business-state, ownership, and catalyst timing uncertain for a 1 year+ ranking. Why now: There is effectively no why-now evidence in this row: the recent evidence review shows zero kept rows after the March 29, 2026 cutoff and no representative articles are provided. Caveats: The phase-2 rationale mentions Amazon acquisition-related articles, but those supporting articles are not included in the available evidence for this row. Scores remain low because absence of evidence is not positive evidence. |
| 26 | HyPrSpace lowweak | Opp 3 Risk 4 | Thesis: Risk is somewhat higher than opportunity because launch development is technically demanding and capital intensive, and the reviewed sources provide no available direct event evidence beyond the membership rationale to confirm de-risking milestones within the recent evidence window. Why now: The reviewed sources does not provide recent evidence window-supported article details for the cited raise and development milestones, so the timing case is under-evidenced. Caveats: No representative articles or direct evidence are available after recent evidence filtering. The opportunity view rests only on the membership rationale rather than article-level evidence available for citation. |
| 27 | Impulse Space mediummedium | Opp 8 Risk 4 | Thesis: Main risk is execution risk after a very large private financing round: the reviewed sources confirms capital raised, but does not provide within the recent evidence window direct evidence of completed commercial deployments or revenue realization. The article context says valuation was undisclosed, adding some uncertainty around terms and expectations. Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis. Evidence
Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here. |
| 28 | Impulse Space lowweak | Opp 4 Risk 4 | Thesis: Risk is not based on direct adverse evidence; instead it reflects defense-program execution uncertainty and lack of currently available corroboration for program status, milestones, or revenue conversion, unavailable in reviewed sources). Why now: Why now is only medium because defense-space prototype work can matter over a 1 year+ horizon, but the reviewed sources' available evidence is empty after recent evidence window, preventing higher-conviction ranking. Caveats: No current evidence is provided for. No direct evidence remained after the recent evidence filter. Potential opportunity rests on membership rationale rather than available corroborated evidence. |
| 29 | Isar Aerospace mediummedium | Opp 5 Risk 4 | Thesis: Risk is also elevated because the same recent context ties the thesis to a near-term launch outcome and milestone execution; the opportunity appears highly contingent on launch success, making binary execution risk material over a 1 year+ horizon. Why now: Recent supporting article context within the recent evidence window supports timing: is dated June 9, 2026 and states Isar raised €270 million and had a June 15-21 Spectrum launch window from Andoya. Date basis is source date. Evidence
Caveats: Evidence is supporting article context only and appears under weak context, not direct dated events. Positive and risk interpretations come from the same article and are not independent confirmation. |
| 30 | ispace lowweak | Opp 3 Risk 4 | Thesis: Reviewed evidence rationale explicitly notes this is ispace's 'second attempt after 2023 failure,' which raises meaningful execution risk for a mission-driven thesis. With no direct positive or negative reviewed evidence, the prior failure context remains the clearest directional risk indicator in the reviewed sources. Why now: The membership support cites: and: The reviewed sources' wording around a second attempt makes mission outcome and execution durability relevant over a 1 year+ horizon, but timing confidence is reduced because no evidence survived into the available set. Caveats: Risk thesis is inferred from reviewed sources rationale mentioning a prior failure, not from available direct negative evidence. No direct evidence confirms current mission status, financing, or customer pipeline. Recency and sequencing of mission milestones cannot be validated from the empty evidence table. |
| 31 | Logos Space Services mediummedium | Opp 6 Risk 4 | Thesis: The same evidence implies substantial execution and engineering risk because the planned network is very large and would use higher-frequency K-, Q- and V-band spectrum that can improve capacity but also pose engineering challenges. Why now: A dated article within the 90-day recent evidence window, with based on April 13, 2026, states that Logos Space Services recently secured FCC approval for a constellation of up to 4,178 broadband satellites and described both target customers and technical architecture, making this a timely strategic-development signal for a 1 year+ horizon. Evidence
Caveats: Evidence is supporting article context, not a richer set of direct dated events/facts. Only one article after recent evidence window; same-article repeated rows are not independent confirmation. |
| 32 | Millennium Space Systems mediummedium | Opp 5 Risk 4 | Thesis: Risk remains moderate because the reviewed sources only provides supporting article context, not direct contract economics, scope allocation to Millennium, or follow-on execution milestones. Why now: The relevant evidence is within the recent evidence window: an April 8, 2026 article said the U.S. Space Force awarded 14 companies more than $1.8 billion in Andromeda contracts and included Boeing's Millennium Space Systems, which is potentially durable over a 1 year+ horizon if tasking converts into meaningful work Evidence
Caveats: Evidence is supporting article context, not a company-specific contract award document or structured positive event row. Reviewed evidence does not show Millennium's individual award size or share of the ceiling value. Same article repeated in weak-context rows is not independent confirmation. |
| 33 | NewOrbit Space mediummedium | Opp 4 Risk 4 | Thesis: Risk is also meaningful because the evidence is undated supporting article context, so recency is uncertain; for a business-state claim like financing and current program maturity, lack of date makes it harder to assess whether the capital raise is still a live catalyst or already absorbed. Why now: Why now is weaker than Aavuus because the article has no publication date. The reviewed sources explicitly says no is available and recency-sensitive claims should be treated cautiously., undated Evidence
Caveats: Evidence is supporting article context only, not direct structured positive event evidence. Publication date is unavailable; recency is uncertain. Single-article support only; no independent confirmation. |
| 34 | NordSpace lowweak | Opp 2 Risk 4 | Thesis: Main risk is evidence insufficiency and likely execution uncertainty around an early-stage space venture rather than confirmed adverse developments; the reviewed sources contain no available direct negative evidence within the recent evidence window and no current dated business-state confirmation, unavailable in reviewed sources). Why now: Why now is weak because coverage data shows zero articles after recent evidence window and zero evidence after the 90-day filter, so there is no current catalyst evidence to support a 1 year+ differentiated view from these reviewed sources. Caveats: No article is provided for the membership-support. No direct positive or negative evidence were available after recent evidence window. Private-company status reduces external validation in these reviewed sources. |
| 35 | NorthStar Earth & Space Inc. lowweak | Opp 2 Risk 4 | Thesis: This row carries elevated information risk because the reviewed sources show no recently retained evidence, no representative articles, and no direct positive or negative evidence, while the ticker/public status implications are time-sensitive and unsupported here. Why now: Why-now is weak because the evidence recent evidence review shows zero kept rows after the 90-day cutoff and the row contains no representative articles or direct evidence, so recency and business state are uncertain in these reviewed sources. Caveats: No evidence were available after the recent evidence window for this row. Any statement about public listing, SPAC timing, or operations would be insufficiently grounded from this row alone. Score is driven by evidence absence, not by documented adverse developments. |
| 36 | Northwood Space mediumweak | Opp 6 Risk 4 | Thesis: Risk is still moderate because the visible reviewed sources does not include the underlying article summary or, so the funding signal lacks fuller context such as use of proceeds, valuation, or milestone cadence. Why now: The rationale references article: and states Northwood Space raised $100 million in a notable spacetech funding deal; that size of financing is plausibly durable over a 1 year+ horizon, though recency cannot be fully validated from the absent article body. Caveats: No representative article or provided in the visible evidence body. No direct evidence after recent evidence window are exposed despite the positive rationale. Funding alone does not prove technical or commercial execution. |
| 37 | Obruta Space Solutions lowweak | Opp 4 Risk 4 | Thesis: Current risk is equal to opportunity because the reviewed sources only shows descriptive company-site context and no direct evidence of contracts, funding, launches, or technical milestones. Without validation, the thesis is still conceptual. Why now: The only dated visible evidence is a company-site page with a May 20, 2026 describing the technology and target markets, which is relevant for strategic positioning but not enough to prove commercial inflection within the next year. Evidence
Caveats: Evidence is company-site descriptive context only. No third-party validation, financing, contract, or deployment evidence is shown. |
| 38 | Observable Space lowweak | Opp 4 Risk 4 | Thesis: The reviewed sources provide no direct operating-niche detail, traction, or milestone evidence beyond the funding mention, so execution risk is relatively elevated despite the financing signal. Why now: Why now is the funding mention tied to article ID: but the reviewed sources provide no, operating specifics, or additional corroborating evidence. Caveats: Funding alone is positive evidence but does not prove business quality. Article ID: is referenced without. |
| 39 | Observable Space mediummedium | Opp 8 Risk 4 | Thesis: Risk remains meaningful because most evidence is supporting source context and neutral facts rather than explicit positive events, and the company still appears to be early-stage, contract-execution dependent, and private. Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon Evidence
Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence. |
| 40 | OMSPACE lowweak | Opp 4 Risk 4 | Thesis: Launch development risk is also high because the evidence only shows an early milestone and a future plan for orbital launch capability by 2027. The reviewed sources contain no retained proof of financing, customer backlog, or follow-on technical milestones, so execution risk is substantial. Why now: The reviewed sources' rationale references article: for a successful sounding-rocket launch and a 2027 orbital-launch target, but the underlying article summary/ is not included here, limiting recency and sequence assessment. Caveats: Evidence is limited to a broad membership rationale without article detail. A sounding-rocket success is meaningfully earlier-stage than an orbital launch business. Risk and opportunity are both elevated relative to peers because the technology path is ambitious but still lightly evidenced. |